Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001364398 | SCV001560545 | uncertain significance | Carnitine palmitoyltransferase II deficiency | 2022-03-29 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with arginine, which is basic and polar, at codon 55 of the CPT2 protein (p.Pro55Arg). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of carnitine palmitoyltransferase II deficiency (PMID: 18550408). ClinVar contains an entry for this variant (Variation ID: 1055686). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CPT2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001751721 | SCV001986129 | uncertain significance | not provided | 2019-08-07 | criteria provided, single submitter | clinical testing | Identified in a patient with a second CPT2 variant with neonatal carnitine palmitoyltransferase II deficiency in published literature (Isackson et al., 2008); The majority of missense variants in this gene are considered pathogenic (Stenson et al., 2014); Not observed in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 25525159, 18550408) |
Fulgent Genetics, |
RCV002488124 | SCV002783495 | uncertain significance | Carnitine palmitoyl transferase II deficiency, severe infantile form; Carnitine palmitoyl transferase II deficiency, myopathic form; Carnitine palmitoyl transferase II deficiency, neonatal form; Encephalopathy, acute, infection-induced, susceptibility to, 4 | 2022-04-20 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003456224 | SCV004179274 | uncertain significance | Encephalopathy, acute, infection-induced, susceptibility to, 4 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003450018 | SCV004179275 | uncertain significance | Carnitine palmitoyl transferase II deficiency, severe infantile form | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003450020 | SCV004179277 | uncertain significance | Carnitine palmitoyl transferase II deficiency, neonatal form | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003450019 | SCV004179278 | uncertain significance | Carnitine palmitoyl transferase II deficiency, myopathic form | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001364398 | SCV002090258 | uncertain significance | Carnitine palmitoyltransferase II deficiency | 2020-11-11 | no assertion criteria provided | clinical testing |